Amid a volatile market where major indices like the S&P 500 and Nasdaq have recently lost ground after a strong start to the week, investors are closely watching for signs of stability and growth. In such an environment, companies with high insider ownership can be particularly appealing, as they often signal confidence from those who know the business best and may offer robust revenue growth potential.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Super Micro Computer (SMCI) | 13.9% | 51.6% |
| SES AI (SES) | 12% | 64.8% |
| Niu Technologies (NIU) | 37.2% | 92.8% |
| FTC Solar (FTCI) | 23.1% | 63% |
| Credo Technology Group Holding (CRDO) | 10.9% | 30.4% |
| Cloudflare (NET) | 10.4% | 44.9% |
| Atour Lifestyle Holdings (ATAT) | 18.3% | 23.7% |
| Astera Labs (ALAB) | 11.9% | 26% |
| AppLovin (APP) | 27.6% | 26.7% |
| Accelerant Holdings (ARX) | 24.9% | 66.1% |
Here's a peek at a few of the choices from the screener.
Niagen Bioscience (NAGE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products with a market cap of $568.63 million.
Operations: The company's revenue is derived from three segments: Ingredients ($28.74 million), Consumer Products ($92.87 million), and Analytical Reference Standards and Services ($3.10 million).
Insider Ownership: 29.4%
Revenue Growth Forecast: 16.9% p.a.
Niagen Bioscience shows potential as a growth company with high insider ownership, evidenced by its robust earnings increase of 1275.7% over the past year and forecasted annual profit growth of 22.8%, outpacing the US market. Recent announcements include a $10 million share repurchase program and an upward revision in sales guidance to 25%-30% for 2025, reflecting management's confidence in future performance despite revenue growth forecasts below 20%.
- Take a closer look at Niagen Bioscience's potential here in our earnings growth report.
- Our valuation report unveils the possibility Niagen Bioscience's shares may be trading at a discount.
Youdao (DAO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Youdao, Inc. is an internet technology company offering online services in content, community, communication, and commerce in China with a market cap of approximately $1.25 billion.
Operations: The company's revenue segments consist of CN¥873.07 million from smart devices, CN¥2.65 billion from learning services, and CN¥2.11 billion from online marketing services.
Insider Ownership: 20.4%
Revenue Growth Forecast: 11.8% p.a.
Youdao's earnings are forecast to grow significantly at 26.6% annually, surpassing the US market average. Despite slower revenue growth of 11.8%, it still outpaces the market's 10.3%. Recently added to the S&P Global BMI Index, Youdao reported improved financials with a net income of CNY 58.98 million for the first half of 2025, reversing last year's losses, indicating positive momentum in its profitability trajectory despite high insider ownership challenges.
- Get an in-depth perspective on Youdao's performance by reading our analyst estimates report here.
- According our valuation report, there's an indication that Youdao's share price might be on the expensive side.
Equity Bancshares (EQBK)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Equity Bancshares, Inc. is the bank holding company for Equity Bank, offering a variety of banking and financial services to both individual and corporate clients, with a market cap of approximately $786.52 million.
Operations: The company's revenue is primarily derived from its banking operations, with Equity Bank generating $191.23 million in revenue.
Insider Ownership: 14.6%
Revenue Growth Forecast: 26.8% p.a.
Equity Bancshares exhibits strong growth prospects with earnings forecast to grow significantly at 79.84% annually, outpacing the US market. Revenue is expected to rise by 26.8% per year, surpassing market averages. Despite a recent net loss of US$29.66 million in Q3 2025, insider buying has exceeded selling over the past three months, reflecting confidence in future performance amid ongoing share buyback activities totaling US$6.8 million recently completed.
- Click to explore a detailed breakdown of our findings in Equity Bancshares' earnings growth report.
- Insights from our recent valuation report point to the potential undervaluation of Equity Bancshares shares in the market.
Summing It All Up
- Embark on your investment journey to our 188 Fast Growing US Companies With High Insider Ownership selection here.
- Interested In Other Possibilities? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Niagen Bioscience might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com